PHIO

PhioB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$1.80

+74.8% vs current

Most likely

Base case

45%

Probability

Target price

$0.85

-17.5% vs current

B-

Bear case

30%

Probability

Target price

$0.40

-61.2% vs current

AI sentiment snapshot

Latest data as of 2026-06-25

AI commentary

Recent flow was dominated by company-distributed Newsfile updates and investor-forum appearances rather than broad third-party validation, so headline visibility improved but evidence quality did not rise proportionally. The packet does not include usable social-sentiment coverage, so social context is not used as a positive signal. The most material update remains the May 7 earnings/business release tied to the 8-K, which reinforced completed Phase 1b dosing, pending final analysis, targeted Q2 FDA interaction, and runway into H1 2027 [#PR-EARNINGS-2026-05-08] [#SEC-8K-2026-05-07]. Thin analyst coverage and loose peers keep this as a monitoring-style biotech setup rather than a high-conviction bullish thesis.

RankAlpha Sentiment Codex - 2026-06-25

Open full AI memo

Evidence flagged

Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.

Impact

tentative

Confidence

AI events

2026-06-30eventPH-762 FDA interaction on next-step study designHigh impact

Management said the Phase 1b trial is complete, final data is being analyzed, and an FDA submission to seek guidance on next-step clinical study design for PH-762 was targeted for Q2 2026; any confirmation, delay, or unexpectedly burdensome feedback is the clearest near-term company-specific inflection [#PR-EARNINGS-2026-05-08] [#SEC-8K-2026-05-07].

2026-09-30catalystTranslation of completed Phase 1b data into a fundable development pathHigh impact

The company highlighted favorable safety and pathology data from the completed dose-escalation study, but final analysis is still pending; stronger-than-expected final framing could help de-risk PH-762, while ambiguous efficacy or added CMC/toxicology requirements would limit upside [#PR-EARNINGS-2026-05-08].

2026-12-31eventRunway and dilution clarity after ATM setupHigh impact

Phio reported about $17 million of cash at March 31, 2026, said prior financings extended runway into the first half of 2027, and disclosed an April 2026 ATM facility for up to $6.36 million; investors likely need clearer evidence that clinical progress can be funded without steep dilution [#PR-EARNINGS-2026-05-08].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-25 • Updated nightlySource: Internal modelMethodology